Webinar | March 23, 2021

A Quality By Design Approach To Viral Clearance: Predicting LRV Through The Use Of A Non-Infectious MVM Surrogate

To determine viral clearance efficacy of biomanufacturing steps, viruses are “spiked” into in-process solutions, processed and analyzed for reduction.  Due to the infectivity of these viruses, studies are conducted in BSL-2 facilities.  Costs and logistics limit analysis during process development.  Discussed here are results from several studies that utilized a non-infectious Mock Virus Particle (MVP) as an MVM surrogate.  The results demonstrated the value to be gained from such a QbD approach during process optimization.

VIEW THE WEBINAR!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: